Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 163

The DOI matches its Crossref record.

A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database*

Open access
Yan, Tristan D., Deraco, Marcello, Elias, Dominique, Glehen, Olivier, Levine, Edward A., Moran, Brendan J., Morris, David L., Chua, Terence C., Piso, Pompiliu, Sugarbaker, Paul H., Peritoneal Surface Oncology Group · 2011 · Cancer

Abstract

BACKGROUND: Currently, no tumor‐node‐metastasis (TNM) staging system exists for patients with diffuse malignant peritoneal mesothelioma (DMPM). The primary objective was to formulate a clinicopathological staging system through the identification of significant prognostic parameters. METHODS: Eight international institutions with prospectively collected data on patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy contributed to the registry. Two hundred ninety‐four patients had complete clinicopathological data and formed the basis of this staging project. RESULTS: Peritoneal cancer index (PCI) was categorized into T 1 (PCI 1‐10), T 2 (PCI 11‐20), T 3 (PCI 21‐30), and T 4 (PCI 30‐39). Twenty‐two patients had positive lymph nodes (N 1) and 12 patients had extra‐abdominal metastases (M 1). The survival for patients with T 1 (PCI 1‐10) N 0 M 0 was significantly superior to the other patients. This group of patients is therefore designated as Stage I. The survival of patients with T 2 (PCI 11‐20) and T 3 (PCI 21‐30), in absence of N 1 or M 1 disease, was similar. This group of patients was categorized as Stage II. The survival of patients with T 4 (PCI 30‐39), N 1, and/or M 1 was similarly poor. This group of patients was therefore categorized as Stage III. Three prognostic factors were independently associated with survival in the multivariate analysis: histological subtype, completeness of cytoreduction, and the proposed TNM staging. The 5‐year survival associated with Stage I, II, and III disease was 87%, 53%, and 29%, respectively. CONCLUSIONS: The proposed TNM staging system resulted in significant stratification of survival by stage when applied to the current multi‐institutional registry data. Cancer 2011. © 2010 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.25640

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 163

Metadata

Authors
Yan, T. D., Deraco, M., Elias, D., Glehen, O., Levine, E. A., Moran, B. J., Morris, D. L., Chua, T. C., Piso, P., Sugarbaker, P. H., & Peritoneal Surface Oncology Group
Venue
Cancer
Publisher
Wiley
Published
2010-11-18
Volume
117
Issue
9
Pages
1855-1863
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2158757628
Cited by
163
References
0
FWCI
7.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database*. https://app.cochat.ai/papers/10.1002/cncr.25640
The paper
Yan, T. D., Deraco, M., Elias, D., Glehen, O., Levine, E. A., Moran, B. J., Morris, D. L., Chua, T. C., Piso, P., Sugarbaker, P. H., & Peritoneal Surface Oncology Group. (2011). A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database*. Cancer. https://doi.org/10.1002/cncr.25640

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.